JP2010519217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519217A5 JP2010519217A5 JP2009549868A JP2009549868A JP2010519217A5 JP 2010519217 A5 JP2010519217 A5 JP 2010519217A5 JP 2009549868 A JP2009549868 A JP 2009549868A JP 2009549868 A JP2009549868 A JP 2009549868A JP 2010519217 A5 JP2010519217 A5 JP 2010519217A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- coating
- pancrelipase
- activity
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 45
- 239000002245 particle Substances 0.000 claims 21
- 239000011248 coating agent Substances 0.000 claims 16
- 238000000576 coating method Methods 0.000 claims 16
- 229940045258 Pancrelipase Drugs 0.000 claims 14
- 108010067035 Pancrelipase Proteins 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 13
- 239000002552 dosage form Substances 0.000 claims 11
- 239000004382 Amylase Substances 0.000 claims 8
- 102000013142 Amylases Human genes 0.000 claims 8
- 108010065511 Amylases Proteins 0.000 claims 8
- 102000033147 ERVK-25 Human genes 0.000 claims 8
- 108091005771 Peptidases Proteins 0.000 claims 8
- 239000004365 Protease Substances 0.000 claims 8
- 235000019418 amylase Nutrition 0.000 claims 8
- 235000019626 lipase activity Nutrition 0.000 claims 8
- 239000004014 plasticizer Substances 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 4
- 229940032147 Starch Drugs 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical group O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 239000000314 lubricant Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 239000008107 starch Substances 0.000 claims 4
- 235000019698 starch Nutrition 0.000 claims 4
- 239000000454 talc Substances 0.000 claims 4
- 229910052623 talc Inorganic materials 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 235000010443 alginic acid Nutrition 0.000 claims 3
- 229920000615 alginic acid Polymers 0.000 claims 3
- 235000010980 cellulose Nutrition 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 239000002274 desiccant Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000002702 enteric coating Substances 0.000 claims 3
- 238000009505 enteric coating Methods 0.000 claims 3
- 229910010272 inorganic material Inorganic materials 0.000 claims 3
- 239000011147 inorganic material Substances 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 claims 2
- 229940063834 Carboxymethylcellulose Sodium Drugs 0.000 claims 2
- 229960001681 Croscarmellose Sodium Drugs 0.000 claims 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 2
- 239000004367 Lipase Substances 0.000 claims 2
- 229940040461 Lipase Drugs 0.000 claims 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 239000000783 alginic acid Substances 0.000 claims 2
- 229960001126 alginic acid Drugs 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 239000004359 castor oil Substances 0.000 claims 2
- 235000019438 castor oil Nutrition 0.000 claims 2
- 230000024881 catalytic activity Effects 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 230000003111 delayed Effects 0.000 claims 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 108090001060 lipase Proteins 0.000 claims 2
- 102000004882 lipase Human genes 0.000 claims 2
- 235000019421 lipase Nutrition 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000002808 molecular sieve Substances 0.000 claims 2
- 239000004033 plastic Substances 0.000 claims 2
- 229920003023 plastic Polymers 0.000 claims 2
- -1 tri-n-butyl acetyl Chemical group 0.000 claims 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 2
- 239000001069 triethyl citrate Substances 0.000 claims 2
- 235000013769 triethyl citrate Nutrition 0.000 claims 2
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 claims 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 claims 1
- 229940069428 ANTACIDS Drugs 0.000 claims 1
- 229940084030 CARBOXYMETHYLCELLULOSE CALCIUM Drugs 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229960000913 Crospovidone Drugs 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N Diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 1
- 229940088598 Enzyme Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 206010025476 Malabsorption Diseases 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229940100467 POLYVINYL ACETATE PHTHALATE Drugs 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001451 Polypropylene glycol Polymers 0.000 claims 1
- 229940077718 Proton pump inhibitors for peptic ulcer and GORD Drugs 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- 229940100486 RICE STARCH Drugs 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229940083542 Sodium Drugs 0.000 claims 1
- 229940091252 Sodium supplements Drugs 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical group CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 1
- 229960002622 Triacetin Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 Xylitol Drugs 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 230000001458 anti-acid Effects 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
- 239000005018 casein Substances 0.000 claims 1
- 235000021240 caseins Nutrition 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- 229910052570 clay Inorganic materials 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 201000003883 cystic fibrosis Diseases 0.000 claims 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 1
- 229940031954 dibutyl sebacate Drugs 0.000 claims 1
- 230000001079 digestive Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 150000004676 glycans Polymers 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 238000005342 ion exchange Methods 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 239000011776 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- KREXGRSOTUKPLX-UHFFFAOYSA-N octadecanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O KREXGRSOTUKPLX-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 239000000612 proton pump inhibitor Substances 0.000 claims 1
- 230000003482 proton pump inhibitor Effects 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N tributyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
Claims (50)
- 複数のコーティングされた粒子を含む組成物であって、前記粒子の各々は腸溶性コーティングでコーティングされたコアを含み、前記コアはパンクレリパーゼを含み、前記コーティング粒子が、6カ月の加速安定性試験後に約25%以下のパンクレリパーゼ酵素活性の損失を示す、組成物。
- 前記組成物の含水率が約3%以下である、請求項1に記載の組成物。
- 前記組成物の水分活性が約0.6以下である、請求項1に記載の組成物。
- 前記腸溶性コーティングが
10〜20重量%の少なくとも1種の腸溶性ポリマー;及び
4〜10重量%のタルク
を含み、前記重量%の各々は前記コーティング粒子の総重量に基づく、請求項2または3に記載の組成物。 - 前記腸溶性コーティングが、前記粒子の総重量に基づいて約1〜2%の少なくとも1種の可塑剤をさらに含む、請求項4に記載の組成物。
- 前記含水率が約2%以下である、請求項2に記載の組成物。
- 前記コーティング粒子が、6カ月の加速安定性試験後に15%以下のパンクレリパーゼ活性の損失を示す、請求項1に記載の組成物。
- 前記コーティングが、少なくとも1種の可塑剤をさらに含む、請求項1に記載の組成物。
- 前記コーティングが、前記コーティング粒子の総重量に基づいて1〜2重量%の少なくとも1種の可塑剤をさらに含む、請求項8に記載の組成物。
- 前記可塑剤が、トリアセチン、クエン酸トリブチル、クエン酸トリエチル、アセチルクエン酸トリn−ブチル、フタル酸ジエチル、セバシン酸ジブチル、ポリエチレングリコール、ポリプロピレングリコール、ヒマシ油、アセチル化モノグリセリド、アセチル化ジグリセリド、およびそれらの混合物から成る群より選択される、請求項9に記載の組成物。
- 前記可塑剤が、クエン酸トリエチルである、請求項10に記載の組成物。
- 前記コアが、結合剤、崩壊剤、潤滑剤、流動促進剤、希釈剤、およびそれらの混合物から成る群より選択される少なくとも1種の医薬的に許容可能な賦形剤をさらに含む、請求項1に記載の組成物。
- 前記結合剤が、デンプン、糖、ラクトース、糖アルコール、キシリトール、ソルビトール、マルチトール、セルロース、微結晶性セルロース、変性セルロース、ヒドロキシプロピルセルロース、カルボキシメチルセルロースナトリウム、アルギン酸、およびポリビニルピロリドンから成る群より選択され、
前記崩壊剤が、2塩基性リン酸カルシウム、2塩基性リン酸カルシウム2水和物、3塩基性リン酸カルシウム、トウモロコシデンプン、アルギン酸、ヒドロキシプロピルセルロース、カルボキシメチルセルロースカルシウム、カルボキシメチルセルロースナトリウム、架橋カルボキシメチルセルロースナトリウム、膨潤性イオン交換樹脂、アルギナート、ホルムアルデヒドカゼイン、セルロース、クロスカルメロースナトリウム、クロスポビドン、微結晶性セルロース、ナトリウムカルボキシメチルデンプン、ナトリウムデンプングリコラート、デンプン、および米デンプンから成る群より選択され、
前記潤滑剤が、ステアリン酸カルシウム、ステアリン酸マグネシウム、ナトリウムステアリルフマラート、ステアリン酸、ステアリン酸亜鉛、タルク、および蝋から成る群より選択され、
前記流動促進剤が、コロイド状二酸化ケイ素およびタルクから成る群より選択され、
前記希釈剤が、マンニトール、スクロース、無水2塩基性リン酸カルシウム、無水2塩基性リン酸カルシウム2水和物、3塩基性リン酸カルシウム、セルロース、ラクトース、炭酸マグネシウム、および微結晶性セルロースから成る群より選択される、請求項12に記載の組成物。 - 前記コアが、前記コーティング粒子の総重量に基づいて、
1〜4重量%の少なくとも1種の崩壊剤;
0.2〜0.6重量%の少なくとも1種の流動促進剤;
2〜6重量%の少なくとも1種の結合剤;及び
0.2〜0.6重量%の少なくとも1種の潤滑剤
をさらに含む、請求項12に記載の組成物。 - 前記少なくとも1種の崩壊剤がクロスカルメロースナトリウムであり、前記少なくとも1種の流動促進剤がコロイド状二酸化ケイ素であり、前記少なくとも1種の結合剤が微結晶性セルロースであり、前記少なくとも1種の潤滑剤がステアリン酸マグネシウムである、請求項14に記載の組成物。
- 前記コアが、前記コーティング粒子の総重量に基づいて0.5〜1.0重量%の少なくとも1種の可塑剤をさらに含む、請求項14に記載の組成物。
- 前記少なくとも1種の可塑剤が、硬化ヒマシ油である、請求項16に記載の組成物。
- 前記コアが、68〜90重量%のパンクレリパーゼを含む、請求項1に記載の組成物。
- 前記パンクレリパーゼが、ブタ由来である、請求項1に記載の組成物。
- 前記腸溶性ポリマーが、セルロースアセタートフタラート、ヒドロキシプロピルメチルセルロースフタラート、ヒドロキシプロピルメチルセルロースアセタートスクシナート、ポリビニルアセタートフタラート、メタクリル酸−メチルメタクリラートコポリマーおよびシェラックから成る群より選択される、請求項1に記載の組成物。
- 前記腸溶性ポリマーが、ヒドロキシプロピルメチルセルロースフタラートである、請求項20に記載の組成物
- 前記パンクレリパーゼが、約1.8〜6.2のプロテアーゼ/リパーゼ活性比を有する、請求項1〜21のいずれか1項に記載の組成物。
- 前記パンクレリパーゼが、約2.0〜6.1のプロテアーゼ/リパーゼ活性比を有する、請求項1〜21のいずれか1項に記載の組成物。
- 前記パンクレリパーゼが、約1.8〜8.2のアミラーゼ/リパーゼ活性比を有する、請求項1〜21のいずれか1項に記載の組成物。
- 前記パンクレリパーゼが、約2.0〜8.2アミラーゼ/リパーゼ活性比を有する、請求項1〜21のいずれか1項に記載の組成物。
- 前記パンクレリパーゼが、約1:10:10〜約10:1:1の範囲のリパーゼ:プロテアーゼ:アミラーゼ活性比を有する、請求項1〜21のいずれか1項に記載の組成物。
- 前記パンクレリパーゼが、
約4,500〜5,500IUのリパーゼ活性、約8,000〜34,000IUのプロテアーゼ活性、及び約8,000〜45,000IUのアミラーゼ活性;
約9,000〜11,000IUのリパーゼ活性、約17,000〜67,000IUのプロテアーゼ活性、及び約17,000〜90,000IUのアミラーゼ活性;
約13,500〜16,500IUのリパーゼ活性、約26,000〜100,000IUのプロテアーゼ活性、及び約26,000〜135,000IUのアミラーゼ活性;または
約18,000〜22,000IUのリパーゼ活性、約35,000〜134,000IUのプロテアーゼ活性、及び約35,000〜180,000IUのアミラーゼ活性
のリパーゼ、プロテアーゼ、およびアミラーゼ活性の組み合わせを含む、請求項1〜21のいずれか1項に記載の組成物。 - 前記コーティング粒子のコアは約2〜5mmの範囲の公称粒径を有し、前記コーティング粒子のコーティング重量は前記コーティング粒子の総重量の約15%である、請求項1〜21のいずれか1項に記載の組成物。
- 前記コーティング粒子のコアが約1〜2mmの範囲の公称粒径を有し、前記コーティング粒子のコーティング重量が前記コーティング粒子の総重量の約22%である、請求項1〜21のいずれか1項に記載の組成物。
- 請求項1〜21のいずれか1項に記載の組成物を含む剤形。
- 前記組成物で充填されたカプセルである、請求項30に記載の剤形。
- 前記カプセルが、セルロース系ポリマー、ヒドロキシプロピルメチルセルロース、デンプン、多糖、プルラン、およびゼラチンから成る群より選択される材料で構成されている、請求項31に記載の剤形。
- 前記カプセルが、約6%以下の含水率のヒドロキシプロピルメチルセルロースからなる、請求項32に記載の剤形。
- 前記カプセルが、約2%以下の含水率のヒドロキシプロピルメチルセルロースからなる、請求項33に記載の剤形。
- 実質的にゼロ過剰充填である、請求項30に記載の剤形。
- 防湿材料で構成されたシール容器と、乾燥剤と、請求項30に記載の少なくとも1種の剤形とを含むパッケージであって、前記組成物の含水率が約3%以下であり、前記乾燥剤と少なくとも1種の剤形が前記シール容器内にある、パッケージ。
- 前記防湿材料が、金属、ガラス、プラスチック、および金属コーティングプラスチックから成る群より選択される、請求項36に記載のパッケージ。
- 前記乾燥剤が、分子ふるい、クレイ、シリカゲル、活性炭、およびそれらの組合せから成る群より選択される、請求項36に記載のパッケージ。
- 前記乾燥剤が分子ふるいである、請求項38に記載のパッケージ。
- 前記剤形が、ヒドロキシプロピルメチルセルロースからなるカプセルである、請求項36に記載のパッケージ。
- 治療または予防を必要とする哺乳動物において消化酵素欠乏症に付随する障害を治療または予防するための薬物を調製するための請求項1に記載の組成物の使用。
- GI管pHを高める薬物の使用をさらに含み、前記パンクレリパーゼ組成物及び前記GI管pHを高める薬物が同じ組成物または異なる組成物中にある、請求項41に記載の使用。
- 前記薬物が、プロトンポンプインヒビターおよび制酸剤から成る群より選択される、請求項42に記載の使用。
- 前記障害が、嚢胞性線維症である、請求項41に記載の使用。
- 前記障害が、前記哺乳動物の脂肪吸収不良である、請求項41に記載の使用。
- 前記薬物が、前記哺乳動物の脂肪吸収係数を高める、請求項41に記載の使用。
- 含水率が1m 3 当たり約3.6g以下の水の雰囲気内で、パンクレリパーゼの粒子を、腸溶性ポリマーと少なくとも1種の無機材料とを含むコーティングでコーティングすることによって、複数の遅延放出粒子を形成することを含む、パンクレリパーゼ組成物の調製方法。
- 前記粒子を、アセトンに溶解した腸溶性ポリマーと少なくとも1種の無機材料との混合物でコーティングする、請求項47に記載の方法。
- 前記少なくとも1種の無機材料が、タルクである、請求項47に記載の方法。
- 前記複数の遅延放出粒子が、約3%以下の含水率または約0.6以下の水分活性を有し、6カ月の加速安定性試験後に15%以下の酵素活性の損失を示す、請求項47に記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90209107P | 2007-02-20 | 2007-02-20 | |
US90209207P | 2007-02-20 | 2007-02-20 | |
US90209307P | 2007-02-20 | 2007-02-20 | |
US60/902,092 | 2007-02-20 | ||
US60/902,093 | 2007-02-20 | ||
US60/902,091 | 2007-02-20 | ||
PCT/IB2008/000770 WO2008102264A2 (en) | 2007-02-20 | 2008-02-20 | Stable digestive enzyme compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013265143A Division JP6082691B2 (ja) | 2007-02-20 | 2013-12-24 | 安定な消化酵素組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010519217A JP2010519217A (ja) | 2010-06-03 |
JP2010519217A5 true JP2010519217A5 (ja) | 2011-03-31 |
JP5966202B2 JP5966202B2 (ja) | 2016-08-10 |
Family
ID=39637607
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009549868A Expired - Fee Related JP5966202B2 (ja) | 2007-02-20 | 2008-02-20 | 安定な消化酵素組成物 |
JP2013265143A Expired - Fee Related JP6082691B2 (ja) | 2007-02-20 | 2013-12-24 | 安定な消化酵素組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013265143A Expired - Fee Related JP6082691B2 (ja) | 2007-02-20 | 2013-12-24 | 安定な消化酵素組成物 |
Country Status (27)
Country | Link |
---|---|
US (9) | US8293229B2 (ja) |
EP (2) | EP2754437B1 (ja) |
JP (2) | JP5966202B2 (ja) |
KR (2) | KR101837010B1 (ja) |
CN (2) | CN101686943B (ja) |
AR (1) | AR065405A1 (ja) |
AU (1) | AU2008218595B2 (ja) |
BR (1) | BRPI0807718B1 (ja) |
CA (1) | CA2677989C (ja) |
CL (1) | CL2008000517A1 (ja) |
CO (1) | CO6220903A2 (ja) |
CR (2) | CR11031A (ja) |
DK (1) | DK2079445T3 (ja) |
ES (2) | ES2560527T3 (ja) |
HK (1) | HK1142818A1 (ja) |
HU (1) | HUE026168T2 (ja) |
IL (1) | IL200407A (ja) |
MX (1) | MX2009008828A (ja) |
MY (1) | MY163469A (ja) |
NZ (2) | NZ579047A (ja) |
PL (1) | PL2079445T3 (ja) |
PT (1) | PT2079445E (ja) |
SG (1) | SG186648A1 (ja) |
TR (1) | TR201808840T4 (ja) |
TW (2) | TWI609693B (ja) |
WO (1) | WO2008102264A2 (ja) |
ZA (1) | ZA200905630B (ja) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632429B1 (en) * | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
IT1319655B1 (it) | 2000-11-15 | 2003-10-23 | Eurand Int | Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione. |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
JP5140586B2 (ja) | 2005-07-29 | 2013-02-06 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 滅菌パンクレアチン粉末の製法 |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
PT2079445E (pt) * | 2007-02-20 | 2016-02-29 | Allergan Pharmaceuticals Internat Ltd | Composições de enzimas digestivas estáveis |
WO2009109856A2 (en) | 2008-03-07 | 2009-09-11 | Axcan Pharma Inc. | Method for detecting infectious parvovirus in pharmaceutical preparations |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US7782646B2 (en) * | 2008-06-30 | 2010-08-24 | International Business Machines Corporation | High density content addressable memory using phase change devices |
ES2732453T3 (es) | 2008-07-01 | 2019-11-22 | Curemark Llc | Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
ES2608050T3 (es) | 2008-12-03 | 2017-04-05 | Synergy Pharmaceuticals Inc. | Formulaciones de agonistas de guanilato ciclasa C y métodos de uso |
GB2480772B (en) | 2009-01-06 | 2013-10-16 | Curelon Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus |
EP2373693A4 (en) | 2009-01-06 | 2012-04-25 | Curelon Llc | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI |
AU2015252099B2 (en) * | 2009-01-06 | 2017-08-10 | Galenagen, Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
CN102231988A (zh) * | 2009-01-29 | 2011-11-02 | 诺尔玛克药物有限责任及股份两合公司 | 细菌脂肪酶药物制剂 |
US9056050B2 (en) * | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
CA2760499C (en) * | 2009-05-07 | 2015-11-03 | United Therapeutics Corporation | Solid formulations of prostacyclin analogs |
WO2011000924A1 (en) | 2009-07-03 | 2011-01-06 | Abbott Products Gmbh | Spray-dried amylase, pharmaceutical preparations comprising the same and use |
US8784884B2 (en) * | 2009-09-17 | 2014-07-22 | Stephen Perrett | Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
EP2509635A4 (en) * | 2009-12-08 | 2013-09-18 | Depomed Inc | GASTRORETENTIVE PHARMACEUTICAL COMPOSITIONS FOR THE EXTENDED RELEASE OF POLYPEPTIDES |
US20110224648A1 (en) * | 2010-03-15 | 2011-09-15 | Angelo Secci | Syringe Filter Cap and Method of Using the Same for Administration of Medication Dosage |
RU2012142134A (ru) * | 2010-03-19 | 2014-04-27 | Апталис Фарма Кэнэда Инк. | Желудочно-резистентные ферментные фармацевтические композиции |
CN102946872A (zh) * | 2010-05-03 | 2013-02-27 | 阿普塔利斯制药有限公司 | 包含含有胰酶的消化酶混合物的微丸组合物 |
UY33548A (es) * | 2010-08-06 | 2012-02-29 | Eurand Pharmaceuticals Inc | Formula nutricional predigerida |
WO2012037380A2 (en) * | 2010-09-15 | 2012-03-22 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
MX348118B (es) * | 2010-10-01 | 2017-05-26 | Aptalis Pharma Ltd | Formulaciones de pancrelipasa con recubrimiento enterico de baja potencia. |
TW201216951A (en) | 2010-10-21 | 2012-05-01 | Aptalis Pharma Ltd | Oral dosing device for administration of medication |
US20140147500A1 (en) * | 2010-11-19 | 2014-05-29 | Joan M. Fallon | Preparation and Use of Combination Enzyme and Gastrointestinal Modulator Delivery Systems |
WO2012145651A2 (en) | 2011-04-21 | 2012-10-26 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
JP2012250926A (ja) * | 2011-06-01 | 2012-12-20 | Nitto Denko Corp | 粒子製剤 |
US9216209B1 (en) * | 2011-06-06 | 2015-12-22 | Kilmer S. McCully | Compositions and method for utilization of thioretinamide in therapy of degenerative diseases of aging |
DK2741766T3 (en) | 2011-08-08 | 2016-01-11 | Aptalis Pharma Ltd | Process for dissolving solid compositions containing digestive enzymes |
CN102357088A (zh) * | 2011-10-26 | 2012-02-22 | 河北山姆士药业有限公司 | 盐酸二甲双胍肠溶片 |
TWI434706B (zh) | 2011-12-15 | 2014-04-21 | Ind Tech Res Inst | 腸溶及腸酵素可分解材料及其製備方法 |
US10350278B2 (en) * | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
JP6263540B2 (ja) * | 2012-09-19 | 2018-01-17 | グレスポ・アクチボラゲットGrespo AB | 脳機能向上用組成物 |
JP6244793B2 (ja) * | 2012-10-24 | 2017-12-13 | 味の素株式会社 | 蛋白質含有食品の製造方法及び蛋白質含有食品改質用の酵素製剤 |
MX2015012078A (es) * | 2013-03-15 | 2016-04-15 | Allergan Pharmaceuticals Internat Ltd | Composicion que contiene enzimas digestivas y nutrientes adecuados para la administracion enteral. |
PL3013931T3 (pl) | 2013-06-25 | 2020-07-13 | Unilever N.V. | Kompozycja zawierająca glutamino-n,n-dioctan (glda), wodę i enzym |
EP3030257B1 (en) | 2013-08-09 | 2020-02-19 | Allergan Pharmaceuticals International Limited | Digestive enzyme composition suitable for enteral administration |
EP3003360B1 (en) * | 2013-11-05 | 2020-10-07 | Allergan Pharmaceuticals International Limited | High potency pancreatin pharmaceutical compositions |
CZ307195B6 (cs) | 2013-11-18 | 2018-03-14 | František Trnka | Farmaceutická kompozice obsahující směs proenzymů a enzymů |
AU2015275860A1 (en) | 2014-06-19 | 2016-11-03 | Aptalis Pharma Ltd. | Methods for removing viral contaminants from pancreatic extracts |
CN104531659B (zh) * | 2014-12-16 | 2018-05-22 | 四川新健康成生物股份有限公司 | 胰蛋白酶消化液、制备方法及即用型痰消化装置 |
GB201501081D0 (en) * | 2015-01-22 | 2015-03-11 | Cilian Ag | Use of enzymes with a wide pH activity range as medicaments for promoting digestion |
US20160331689A1 (en) * | 2015-05-12 | 2016-11-17 | SE Tylose USA, Inc. | Aqueous enteric coating composition |
WO2017052455A1 (en) | 2015-09-23 | 2017-03-30 | Anara Ab | Amylase fragments for blood glucose control |
AU2017240190A1 (en) * | 2016-03-31 | 2018-09-20 | Sorriso Pharmaceuticals, Inc. | Compositions |
EP3251687A1 (en) | 2016-06-01 | 2017-12-06 | Centrum Innowacji Edoradca Sp. z o.o. Spolka Komandytowa | Bioactive peptides for blood glucose control |
DE102017104482A1 (de) * | 2017-03-03 | 2018-09-06 | Nordmark Arzneimittel Gmbh & Co. Kg | Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug |
FR3079146B1 (fr) | 2018-03-23 | 2020-04-17 | Karim Ioualalen | Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive. |
CN108977429B (zh) * | 2018-09-14 | 2021-08-03 | 中国水产科学研究院黄海水产研究所 | 一种海洋微生物ys2071脂肪酶稳定性保护剂 |
WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
CA3144566A1 (en) | 2019-06-21 | 2020-12-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
US11541009B2 (en) * | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
CN113749086A (zh) * | 2021-08-27 | 2021-12-07 | 佛山科学技术学院 | DNase I及其药学上可接受的盐在制备精液稀释的药物中的应用 |
WO2023168316A1 (en) * | 2022-03-04 | 2023-09-07 | Michael Ogburn | Enteric coated dry powdered cannabinoid formulations |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US44968A (en) * | 1864-11-08 | Improvement in couplings for whiffletrees | ||
US24660A (en) * | 1859-07-05 | Setting gas-meteks in the walls of buildings | ||
US19417A (en) * | 1858-02-23 | Improvement in cotton-gins | ||
US101562A (en) * | 1870-04-05 | Chaeles alden | ||
US2751330A (en) | 1952-08-27 | 1956-06-19 | Armour & Co | Use of a salt in the extraction slurry in recovering proteolytic enzymes from pancreas gland material |
GB1342409A (en) | 1970-07-23 | 1974-01-03 | Ciba Geigy Ag | Flowable pancreatin preparation of low microorgan ism content and a process for its manufacture |
GB1509866A (en) * | 1975-06-10 | 1978-05-04 | Johnson & Johnson | Enteric coated digestive enzyme compositions |
US4237229A (en) | 1975-06-10 | 1980-12-02 | W. R. Grace & Co. | Immobilization of biological material with polyurethane polymers |
GB1590432A (en) | 1976-07-07 | 1981-06-03 | Novo Industri As | Process for the production of an enzyme granulate and the enzyme granuate thus produced |
JPS5535031A (en) | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
DE2923279C2 (de) | 1979-06-08 | 1987-07-09 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel |
JPS5855125B2 (ja) | 1980-03-10 | 1983-12-08 | 信越化学工業株式会社 | 固形薬剤用腸溶性コ−テイング剤組成物 |
JPS5885159A (ja) | 1981-11-17 | 1983-05-21 | Furointo Sangyo Kk | 溶出試験装置 |
DE3377506D1 (en) | 1982-12-30 | 1988-09-01 | Nordmark Arzneimittel Gmbh | Process for obtaining pancreatin |
US4447412A (en) | 1983-02-01 | 1984-05-08 | Bilton Gerald L | Enzyme-containing digestive aid compostions |
US4704295A (en) * | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
DE3445301A1 (de) | 1984-12-12 | 1986-06-12 | Hoechst Ag, 6230 Frankfurt | Pankreasenzympraeparate und verfahren zu deren herstellung |
WO1987004184A1 (en) | 1985-12-27 | 1987-07-16 | Showa Denko Kabushiki Kaisha | Process for granulating enzyme |
ATE109659T1 (de) * | 1986-03-21 | 1994-08-15 | Eurasiam Lab | Arzneimittelzusammensetzungen. |
US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
FR2603804B1 (fr) | 1986-09-17 | 1989-10-27 | Jouveinal Sa | Lipases et extraits lipasiques, leur procede de preparation et leur application en therapeutique |
IT1205716B (it) * | 1987-01-21 | 1989-03-31 | Samil Spa | Procedimento per la preparazione di microsfere gastroresistenti ed enterosolubili di enzima digestivo e preparato faramceutico a microsfere cosi' prodotto |
DK435687D0 (da) | 1987-08-21 | 1987-08-21 | Novo Industri As | Enzymholdigt granulat og fremgangsmaade til fremstilling deraf |
US5733763A (en) | 1988-08-19 | 1998-03-31 | Novo Nordisk A/S | Enzyme granulate formed of an enzyme-containing core and an enzyme-containing shell |
DK78189D0 (da) | 1989-02-20 | 1989-02-20 | Novo Industri As | Enzymholdigt granulat og fremgangsmaade til fremstilling deraf |
DK78089D0 (da) | 1989-02-20 | 1989-02-20 | Novo Industri As | Detergentholdigt granulat og fremgangsmaade til fremstilling deraf |
DK306289D0 (da) | 1989-06-21 | 1989-06-21 | Novo Nordisk As | Detergentadditiv i granulatform |
DE3927286C2 (de) | 1989-08-18 | 1997-07-24 | Roehm Gmbh | Wäßrige Enzym-Flüssigformulierungen |
KR100229754B1 (ko) * | 1989-11-24 | 1999-11-15 | 샬러 한스, 하우스 한스 루돌프 | 판크레아틴구형입자, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
IT1246350B (it) * | 1990-07-11 | 1994-11-17 | Eurand Int | Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili |
JPH0790565B2 (ja) | 1991-08-06 | 1995-10-04 | 株式会社日本製鋼所 | 樹脂成形プレスのスライド制御方法及びその装置 |
US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
WO1993007859A1 (en) | 1991-10-23 | 1993-04-29 | Warner-Lambert Company | Novel pharmaceutical pellets and process for their production |
SE9200858L (sv) | 1992-03-20 | 1993-09-21 | Kabi Pharmacia Ab | Metod för framställning av pellets med fördröjd frisättning |
HRP930935A2 (en) | 1992-06-11 | 1994-12-31 | Astra Ab | New dna sequences |
US5260074A (en) * | 1992-06-22 | 1993-11-09 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
US5460812A (en) | 1992-06-22 | 1995-10-24 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
US5578304A (en) | 1992-06-22 | 1996-11-26 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
US5308832A (en) | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
DE4227385A1 (de) * | 1992-08-19 | 1994-02-24 | Kali Chemie Pharma Gmbh | Pankreatinmikropellets |
JP3264027B2 (ja) | 1993-02-24 | 2002-03-11 | ソニー株式会社 | 放電セル及びその製造方法 |
US5955448A (en) * | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
RU94017352A (ru) | 1994-05-11 | 1996-07-27 | Товарищество с ограниченной ответственностью "Инвест" | Способ лечения онкологических больных, перенесших операцию на желудочно-кишечном тракте |
DE4422433A1 (de) | 1994-06-28 | 1996-01-04 | Cognis Bio Umwelt | Mehrenzymgranulat |
EP0937648A3 (en) | 1994-08-05 | 2001-01-17 | West Pharmaceutical Services Cornwall Limited | Container for moisture-sensitive material |
US5733575A (en) * | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
WO1996038170A1 (en) | 1995-05-31 | 1996-12-05 | Medzyme N.V. | Composition to improve digestibility and utilisation of nutrients |
US6057139A (en) * | 1995-06-29 | 2000-05-02 | Mcneil-Ppc, Inc. | Preblend of microcrystalline cellulose and lactase for making tablets |
US5665428A (en) | 1995-10-25 | 1997-09-09 | Macromed, Inc. | Preparation of peptide containing biodegradable microspheres by melt process |
US5750104A (en) * | 1996-05-29 | 1998-05-12 | Digestive Care Inc. | High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith |
DE19622131A1 (de) | 1996-06-01 | 1997-12-04 | Solvay Enzymes Gmbh & Co Kg | Neue Enzymgranulate |
EP0938657A4 (en) | 1996-06-04 | 1999-10-27 | Euro Celtique Sa | IMPROVEMENTS OF DETECTION SYSTEMS AND METHOD FOR PREDICTING THE RESOLUTION CURVE OF A MEDICINE OF A PHARMACEUTICAL DOSAGE FORM |
JPH1023888A (ja) | 1996-07-10 | 1998-01-27 | Kao Corp | 酵素造粒物の製造方法 |
US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
GB9623205D0 (en) * | 1996-11-07 | 1997-01-08 | Eurand Int | Novel pharmaceutical compositions |
CA2198317C (en) | 1997-02-24 | 2003-01-07 | Mouhsine El Abboudi | Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof |
JPH10295374A (ja) | 1997-04-30 | 1998-11-10 | Amano Pharmaceut Co Ltd | 安定な酵素顆粒の製造法 |
DE19721467A1 (de) | 1997-05-22 | 1998-11-26 | Basf Ag | Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe |
SE9702338D0 (sv) | 1997-06-18 | 1997-06-18 | Astra Ab | An analytical method and industrial process including the same |
ES2137862B1 (es) | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
JP3611456B2 (ja) | 1997-09-30 | 2005-01-19 | 日研化学株式会社 | テオフィリン徐放性錠剤 |
KR19990072826A (ko) | 1998-02-26 | 1999-09-27 | 우재영 | 판크레아틴장용코팅과립의제조방법 |
US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
JPH11315043A (ja) | 1998-04-30 | 1999-11-16 | Lion Corp | ヒドロキシエーテル化合物の製造方法及び洗浄剤組成物 |
US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
US20010024660A1 (en) * | 1999-09-29 | 2001-09-27 | Ismat Ullah | Enteric coated pharmaceutical composition and method of manufacturing |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
CA2653839A1 (en) | 1998-11-02 | 2000-05-11 | John G. Devane | Multiparticulate modified release composition |
WO2001025411A1 (en) | 1999-10-01 | 2001-04-12 | Novozymes A/S | Spray dried enzyme product |
US20010046493A1 (en) | 2000-02-24 | 2001-11-29 | Alex Margolin | Lipase-containing composition and methods of use thereof |
WO2001070047A1 (en) | 2000-03-24 | 2001-09-27 | Société des Produits Nestlé S.A. | Nutritional composition comprising hydrolysed protein |
WO2001074980A2 (en) | 2000-04-03 | 2001-10-11 | Novozymes A/S | Enzyme tablets for cleaning improvement |
IT1319655B1 (it) | 2000-11-15 | 2003-10-23 | Eurand Int | Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione. |
AR032392A1 (es) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. |
US20020143058A1 (en) * | 2001-01-24 | 2002-10-03 | Taro Pharmaceutical Inductries Ltd. | Process for preparing non-hygroscopic sodium valproate composition |
AUPR272901A0 (en) | 2001-01-25 | 2001-02-22 | Gainful Plan Limited | Method of preparing biological materials and preparations produced using same |
EP1279402B1 (en) | 2001-07-26 | 2006-11-29 | Ethypharm | Coated granules of allylamine-or benzylamine-anti-mycotics, process for preparation thereof and orodispersible tablets containing said coated granules |
JP4187085B2 (ja) | 2001-08-24 | 2008-11-26 | 三菱電機株式会社 | 車両用乗員保護装置 |
US20040197321A1 (en) | 2002-03-19 | 2004-10-07 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
CN1156308C (zh) | 2002-04-19 | 2004-07-07 | 北京世诺医药科技有限公司 | 多酶组合胶囊 |
US20040121010A1 (en) | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
EP1579771A4 (en) | 2002-11-29 | 2006-02-22 | Freund Corp | LAC-COATING MATERIALS WATER-BASED, METHOD FOR PRODUCING WITH THE COATING MATERIAL COATED FOOD, PROCESS FOR THEIR, COATED DRUGS, METHOD FOR PRODUCING, GLOSS COATING COMPOSITION FOR OIL-BASED SNACK PRODUCT, GLOSS COATING PROCESS AND GLOSS COATED OIL CONTAINING SNACK PRODUCT |
CA2419572A1 (en) | 2003-02-18 | 2004-08-18 | Axcan Pharma Inc. | High dosage protease formulation |
US20040213847A1 (en) | 2003-04-23 | 2004-10-28 | Matharu Amol Singh | Delayed release pharmaceutical compositions containing proton pump inhibitors |
US6955520B2 (en) * | 2003-07-22 | 2005-10-18 | Delaware Capital Formation, Inc. | Refuse collection vehicle and method with stackable refuse storage container |
WO2005042012A1 (en) | 2003-10-29 | 2005-05-12 | Altus Pharmaceuticals Inc. | Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain |
US7670624B2 (en) | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
BRPI0509148B8 (pt) | 2004-03-22 | 2021-05-25 | Abbott Products Gmbh | composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina contendo tensoativos, seus usos e respectivos processos de fabricação |
US20050281876A1 (en) * | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
US20060198838A1 (en) | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
PT2198880T (pt) | 2004-10-14 | 2017-01-04 | Lilly Co Eli | Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática |
US20070025977A1 (en) | 2005-07-21 | 2007-02-01 | Mulberg Andrew E | Method of treating steatorrhea in infants |
KR101199196B1 (ko) | 2005-07-25 | 2012-11-07 | (주)다산메디켐 | 구형의 판크레아틴 과립의 제조방법 |
JP5140586B2 (ja) | 2005-07-29 | 2013-02-06 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 滅菌パンクレアチン粉末の製法 |
AU2006281415B2 (en) | 2005-08-15 | 2012-01-19 | Abbott Laboratories Gmbh | Pancreatin micropellet cores suitable for enteric coating |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
NZ565960A (en) | 2005-08-15 | 2012-03-30 | Solvay Pharm Gmbh | Controlled release pharmaceutical compositions for acid labile drugs |
WO2007053619A2 (en) | 2005-11-01 | 2007-05-10 | Bio-Cat, Inc. | A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency |
US20070141151A1 (en) | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
WO2007074856A1 (ja) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | 口腔内崩壊性固形製剤の製造法 |
SG169334A1 (en) | 2006-01-21 | 2011-03-30 | Abbott Gmbh & Co Kg | Dosage form and method for the delivery of drugs of abuse |
MX2008015031A (es) | 2006-05-26 | 2008-12-05 | Nestec Sa | Metodos de uso y composiciones nutritivas de extracto de touchi. |
CN103168928A (zh) | 2006-08-07 | 2013-06-26 | 诺维信公司 | 用于动物饲料的酶团粒 |
KR100804096B1 (ko) | 2006-08-31 | 2008-02-18 | (주)아모레퍼시픽 | 고농도 계면활성제 계에서도 안정한 효소 캡슐 제제를포함하는 피부 세정용 조성물 및 그 제조방법 |
JP5038731B2 (ja) | 2007-01-23 | 2012-10-03 | 株式会社ハタ研削 | 光分岐接続装置 |
US20080199448A1 (en) | 2007-02-16 | 2008-08-21 | Ross Mairi R | Enzyme composition for improving food digestion |
RU2445952C2 (ru) | 2007-02-20 | 2012-03-27 | Юранд Фармасьютикалз Лимитед | Стабильные композиции пищеварительных ферментов |
PT2079445E (pt) | 2007-02-20 | 2016-02-29 | Allergan Pharmaceuticals Internat Ltd | Composições de enzimas digestivas estáveis |
US20090117180A1 (en) * | 2007-02-20 | 2009-05-07 | Giovanni Ortenzi | Stable digestive enzyme compositions |
WO2008127567A1 (en) | 2007-04-13 | 2008-10-23 | Beth Israel Deaconess Medical Center, Inc. | Novel nutritional food products for improved digestion and intestinal absorption |
WO2009109856A2 (en) | 2008-03-07 | 2009-09-11 | Axcan Pharma Inc. | Method for detecting infectious parvovirus in pharmaceutical preparations |
US8658163B2 (en) * | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
CN101430279A (zh) | 2008-10-27 | 2009-05-13 | 江南大学 | 荧光分光光度法筛选催化非水相体系转酯化反应用酶的方法 |
US8784884B2 (en) | 2009-09-17 | 2014-07-22 | Stephen Perrett | Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency |
JP2011093845A (ja) | 2009-10-29 | 2011-05-12 | 宏之 ▲今▼西 | 胃瘻用注入剤及びその注入装置 |
EP2509635A4 (en) | 2009-12-08 | 2013-09-18 | Depomed Inc | GASTRORETENTIVE PHARMACEUTICAL COMPOSITIONS FOR THE EXTENDED RELEASE OF POLYPEPTIDES |
RU2012142134A (ru) | 2010-03-19 | 2014-04-27 | Апталис Фарма Кэнэда Инк. | Желудочно-резистентные ферментные фармацевтические композиции |
GB201006178D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
EP2558216B1 (en) | 2010-04-14 | 2020-03-18 | Dow Global Technologies LLC | Dispensing device for both froth and non-froth coatings |
TW201210517A (en) | 2010-08-06 | 2012-03-16 | Aptalis Pharma Ltd | Predigested nutritional formula |
UY33548A (es) | 2010-08-06 | 2012-02-29 | Eurand Pharmaceuticals Inc | Formula nutricional predigerida |
MX348118B (es) | 2010-10-01 | 2017-05-26 | Aptalis Pharma Ltd | Formulaciones de pancrelipasa con recubrimiento enterico de baja potencia. |
TW201216951A (en) | 2010-10-21 | 2012-05-01 | Aptalis Pharma Ltd | Oral dosing device for administration of medication |
PL3199024T3 (pl) | 2011-03-27 | 2019-05-31 | Cellresin Tech Llc | Zastosowanie kompozycji cyklodekstryny i stosowne sposoby |
DK2741766T3 (en) | 2011-08-08 | 2016-01-11 | Aptalis Pharma Ltd | Process for dissolving solid compositions containing digestive enzymes |
CN103060296B (zh) | 2012-12-30 | 2014-05-21 | 青岛九龙生物医药有限公司 | 从动物胰脏中提取胰蛋白酶的方法 |
MX2015012078A (es) | 2013-03-15 | 2016-04-15 | Allergan Pharmaceuticals Internat Ltd | Composicion que contiene enzimas digestivas y nutrientes adecuados para la administracion enteral. |
AU2014304176A1 (en) | 2013-07-22 | 2016-02-11 | Aptalis Pharma Ltd. | High potency pancreatin pharmaceutical compositions |
EP3030257B1 (en) | 2013-08-09 | 2020-02-19 | Allergan Pharmaceuticals International Limited | Digestive enzyme composition suitable for enteral administration |
EP3003360B1 (en) | 2013-11-05 | 2020-10-07 | Allergan Pharmaceuticals International Limited | High potency pancreatin pharmaceutical compositions |
AU2015275860A1 (en) | 2014-06-19 | 2016-11-03 | Aptalis Pharma Ltd. | Methods for removing viral contaminants from pancreatic extracts |
-
2008
- 2008-02-20 PT PT87193926T patent/PT2079445E/pt unknown
- 2008-02-20 AU AU2008218595A patent/AU2008218595B2/en not_active Ceased
- 2008-02-20 AR ARP080100693A patent/AR065405A1/es not_active Application Discontinuation
- 2008-02-20 EP EP14150794.7A patent/EP2754437B1/en active Active
- 2008-02-20 NZ NZ579047A patent/NZ579047A/en not_active IP Right Cessation
- 2008-02-20 US US12/034,491 patent/US8293229B2/en active Active
- 2008-02-20 ES ES08719392.6T patent/ES2560527T3/es active Active
- 2008-02-20 US US12/034,480 patent/US8246950B2/en active Active
- 2008-02-20 DK DK08719392.6T patent/DK2079445T3/en active
- 2008-02-20 TR TR2018/08840T patent/TR201808840T4/tr unknown
- 2008-02-20 CN CN200880012762.6A patent/CN101686943B/zh not_active Expired - Fee Related
- 2008-02-20 SG SG2012091583A patent/SG186648A1/en unknown
- 2008-02-20 MY MYPI20093433A patent/MY163469A/en unknown
- 2008-02-20 BR BRPI0807718-5A patent/BRPI0807718B1/pt not_active IP Right Cessation
- 2008-02-20 MX MX2009008828A patent/MX2009008828A/es active IP Right Grant
- 2008-02-20 US US12/034,488 patent/US8221747B2/en active Active
- 2008-02-20 KR KR1020157004820A patent/KR101837010B1/ko active IP Right Grant
- 2008-02-20 TW TW102138934A patent/TWI609693B/zh not_active IP Right Cessation
- 2008-02-20 CL CL200800517A patent/CL2008000517A1/es unknown
- 2008-02-20 TW TW097105993A patent/TWI421090B/zh not_active IP Right Cessation
- 2008-02-20 CN CN201410059861.7A patent/CN103933555B/zh not_active Expired - Fee Related
- 2008-02-20 NZ NZ598477A patent/NZ598477A/xx not_active IP Right Cessation
- 2008-02-20 CA CA2677989A patent/CA2677989C/en active Active
- 2008-02-20 WO PCT/IB2008/000770 patent/WO2008102264A2/en active Application Filing
- 2008-02-20 PL PL08719392T patent/PL2079445T3/pl unknown
- 2008-02-20 KR KR1020097019590A patent/KR101670016B1/ko active IP Right Grant
- 2008-02-20 HU HUE08719392A patent/HUE026168T2/en unknown
- 2008-02-20 JP JP2009549868A patent/JP5966202B2/ja not_active Expired - Fee Related
- 2008-02-20 ES ES14150794.7T patent/ES2674681T3/es active Active
- 2008-02-20 EP EP08719392.6A patent/EP2079445B1/en active Active
-
2009
- 2009-08-13 ZA ZA2009/05630A patent/ZA200905630B/en unknown
- 2009-08-13 IL IL200407A patent/IL200407A/en active IP Right Grant
- 2009-09-17 CR CR11031A patent/CR11031A/es unknown
- 2009-09-18 CO CO09101677A patent/CO6220903A2/es not_active Application Discontinuation
- 2009-10-09 US US12/576,930 patent/US7658918B1/en active Active
-
2010
- 2010-07-08 US US12/832,596 patent/US8562978B2/en active Active
- 2010-09-29 HK HK10109367.4A patent/HK1142818A1/xx not_active IP Right Cessation
-
2011
- 2011-02-02 US US13/019,860 patent/US8562981B2/en active Active
- 2011-02-02 US US13/019,856 patent/US8562980B2/en active Active
- 2011-02-02 US US13/019,844 patent/US8562979B2/en active Active
-
2013
- 2013-10-02 US US14/043,923 patent/US10206882B2/en active Active
- 2013-12-24 JP JP2013265143A patent/JP6082691B2/ja not_active Expired - Fee Related
-
2014
- 2014-09-16 CR CR20140422A patent/CR20140422A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010519217A5 (ja) | ||
Chen et al. | Tablets of multi-unit pellet system for controlled drug delivery | |
EP2098250B1 (en) | Orally disintegrating solid preparation | |
US9241910B2 (en) | Orally-disintegrating solid preparation | |
JP5059748B2 (ja) | 時限パルス放出システム | |
US10238605B2 (en) | Dry coated tablet | |
NZ270737A (en) | Enteric coated tablet: active core, erodible polymer layer containing cellulose ether derivative, and enteric outer coating | |
KR20130124344A (ko) | 구강내 붕괴정 | |
JP6364406B2 (ja) | 口腔内崩壊錠 | |
AU2015372434B2 (en) | Method of treatment | |
JP2009519334A (ja) | ランソプラゾール経口崩壊錠剤 | |
WO2012092486A2 (en) | Modified release benzimidazole formulations | |
CA3160862A1 (en) | Dosage form for use in treating or preventing of a disease | |
JP2009524592A (ja) | ランソプラゾール経口崩壊錠剤 | |
EP2331084A1 (en) | Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof | |
US20110177164A1 (en) | Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof | |
WO2011144975A1 (en) | Multi-unit compositions | |
RU2009135038A (ru) | Стабильные композиции пищеварительных ферментов | |
CA2877190C (en) | Medicament form for release of active ingredients | |
US20110150945A1 (en) | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer | |
CN105816436B (zh) | 一种泮托拉唑肠溶微丸、泮托拉唑肠溶缓控释片剂及其制备方法 | |
US9504655B2 (en) | Capsule dosage form of metoprolol succinate | |
WO2009065130A2 (en) | Modified release formulations of diltiazem | |
KR20200033773A (ko) | 방습 코팅용 조성물 | |
Kandalgaonkar et al. | Enteric Coating Formulation Design of Omeprazole Tablets |